The therapeutic landscape of EGFR-mutant NSCLC continues to evolve rapidly, with several novel therapies, resistance targets, and synergistic combinations—including ADCs, bispecific antibodies, chemotherapy, and anti-angiogenic agents—under investigation to further refine optimal treatment sequencing. Here, EGFR is linked to non-small cell lung carcinoma.